Home › Compare › MMRTY vs ABBV
MMRTY yields 99.31% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 7
Combined, MMRTY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MMRTY + ABBV for your $10,000?
Massmart Holdings Limited operates as a retail and wholesale company in South Africa and the rest of Africa. It operates through four segments: Game, Builders, Massmart Wholesale, and Sale Businesses. The Game segment operates as a general merchandise discounter and food retailer. The Builders segment operates as a home improvement retailer and building materials supplier. The Massmart Wholesale segment engages in the warehouse club and food wholesale business. The Sale Businesses segment operates as a food retailer and wholesaler. The company also engages in the management, investment, and finance businesses; and warehousing and mass merchandising business. As of December 26, 2021, it operated 408 stores under the Makro, Game, Jumbo, Trident, Shield, Saverite, Builders Warehouse, Builders Express, Builders Trade Depot, Builders Superstore, Rhino, Fruitspot, and Cambridge Food brands. The company was founded in 1990 and is headquartered in Sandton, South Africa. Massmart Holdings Limited is a subsidiary of Main Street 830 Proprietary Limited.
Full MMRTY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.